Advances in subcutaneous infusion pump therapy for PAH

Robyn Kalda
2 days ago
1 min read

Infusion pump technology for subcutaneous prostacyclin analog therapy has improved, with improved user experiences, simplified priming processes, easier filling, capability for lower doses, and better safety alerts and alarms. This may allow more pulmonary arterial hypertension (PAH) patients to safely manage and benefit from subcutaneous prostacyclin analogs.

Read the Advances in Therapy commentary

Recent Posts

SPP1 improves risk assessment for pregnant people with PAH

Secreted phosphoprotein 1 (SPP1) levels were higher in patients with PAH, and SPP1 levels were associated with disease severity. Patients who had postpartum adverse events had higher SPP1 concentratio

In PAH, palliative care discussions need to be proactive

A survey of 200 people in the United States living with pulmonary arterial hypertension (PAH) found that 85% had never discussed palliative care with their healthcare provider, even though nearly nine

Endoplasmic reticulum stress induces a pathway that accelerates PAH progression

This study found that endoplasmic reticulum stress in lung blood vessels may contribute to pulmonary arterial hypertension (PAH) by triggering pyroptosis and damaging blood vessels. In rats, blocking

Comments